We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients.
- Authors
Yankun Zhu; Mingyao Meng; Zongliu Hou; Wenju Wang; Lin Li; Aoran Guan; Ruotian Wang; Weiwei Tang; Fang Yang; Yiyi Zhao; Hui Gao; Hui Xie; Ruhong Li; Jing Tan
- Abstract
Background: Expansion and activation of cytotoxic T lymphocytes (CTLs) in vitro represents a promising immunotherapeutic strategy, and CTLs can be primed by dendritic cells (DCs) loaded with tumor-associated antigens (TAAs) transformed by recombinant adeno-associated virus (rAAV). This study aimed to explore the impact of rAAV-DC-induced CTLs on prognosis of CRC and to explore factors associated with prognosis. Methods: This prospective observational study included patients operated for CRC at Yan'an Hospital Affiliated to Kunming Medical University between 2016 and 2019. The primary outcome was progression-free survival (PFS), secondary outcomes were overall survival (OS) and adverse events. Totally 49 cases were included, with 29 and 20 administered rAAV-DC-induced CTL and chemotherapy, respectively. Results: After 37-69 months of follow-up (median, 54 months), OS (P=0.0596) and PFS (P=0.0788) were comparable between two groups. Mild fever occurred in 2 (6.9%) patients administered CTL infusion. All the chemotherapy group experienced mild-to-moderate adverse effects, including vasculitis (n=20, 100%), vomiting (n=5, 25%), nausea (n=17, 85%) and fatigue (n=17, 85%). Conclusions: Lymphatic metastasis (hazard ratio [HR]=4.498, 95% confidence interval [CI]: 1.290-15.676; P=0.018) and lower HLA-I expression (HR=0.294, 95%CI: 0.089-0.965; P=0.044) were associated with poor OS in the CTL group. CTLs induced by rAAV-DCs might achieve comparable effectiveness in CRC patients compare to chemotherapy, cases with high tumor-associated HLA-I expression and no lymphatic metastasis were more likely to benefit from CTLs.
- Subjects
CYTOTOXIC T cells; LYMPHATIC metastasis; CANCER prognosis; HISTOCOMPATIBILITY class I antigens; IMMUNOTHERAPY; PROGRESSION-free survival
- Publication
Frontiers in Oncology, 2023, Vol 13, p01
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2023.1122669